Rhythm Pharmaceuticals (RYTM) Total Liabilities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Total Liabilities data on file, last reported at $204.7 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 8.45% year-over-year to $204.7 million in Q1 2026; TTM through Mar 2026 was $204.7 million, a 8.45% decrease from a year earlier, with the FY2025 full-year figure at $210.2 million, down 7.71% from the prior year.
• Total Liabilities for Q1 2026 stood at $204.7 million, down from $210.2 million in the prior quarter.
• Over the last five years, Total Liabilities for RYTM reached as high as $239.2 million in Q2 2025 and fell as low as $49.1 million in Q1 2022.
• Historically, Total Liabilities has averaged $168.1 million across 5 years, with a median of $197.1 million in 2024.
• Across the five-year window, Total Liabilities soared 223.06% in 2022 and retreated 8.45% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $118.2 million in 2022, then soared by 37.87% to $163.0 million in 2023, then soared by 39.72% to $227.7 million in 2024, then slipped by 7.71% to $210.2 million in 2025, then retreated by 2.6% to $204.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $204.7 million in Q1 2026, $210.2 million in Q4 2025, and $211.2 million in Q3 2025.